T-activin in combined therapy of type I diabetes mellitus

2019 ◽  
Vol 43 (3) ◽  
pp. 23-25
Author(s):  
V. I. Novikov ◽  
V. A. Shostak
Keyword(s):  
Time Course ◽  
Type I Diabetes ◽  
Combined Therapy ◽  
Insulin Dose ◽  
Type I ◽  
T Helper ◽  
Daily Insulin ◽  
Immune Parameters ◽  
Daily Insulin Dose

The effects of t-activin on the time course of immunohormonal, metabolic, and clinical parameters were studied in patients with newly diagnosed type I diabetes (n = 50, aged 17 to 35, followed up for 2 years; controls: 20 patients with type 1 disease treated traditionally). An appreciable decrease of basal and stimulated levels of C-peptide, shifted T-helper to T-supprcssor ratio caused by a decrease of T-suppressor level, and an increase of the immunoregulatory index were observed at the debut of type 1 diabetes; these shifts gave grounds sufficient to prescribe t-activin. Tactivin therapy for 2 years led to a decrease of the T-helper/T-suppressor imbalance due to an increase of the T-suppressor content, normalization of IRI, increase of the basal and stimulated C-peptidc levels, normalization of HbAlc at a daily insulin dose of 0.4 U/kg, and a stable course of the disease. In the controls the immune parameters and hormones did not normalize, daily insulin dose was 0.6 U/kg, and the disease course unstable. Hence, t-activin not only corrected the immunity, but metabolism as well, which resulted in stimulation of repair regeneration of pancreatic p-cells.

Correlations of cholecalciferol-levels, daily insulin dose and clinical features in patients with Type 1 diabetes mellitus

2013 ◽  
Vol 8 (S 01) ◽  
Author(s):  
D Bogdanou ◽  
M Penna-Martinez ◽  
F Shioghi ◽  
M Sandler ◽  
K Badenhoop
Keyword(s):  
Diabetes Mellitus ◽  
Type 1 Diabetes ◽  
Type 1 Diabetes Mellitus ◽  
Clinical Features ◽  
Insulin Dose ◽  
Daily Insulin ◽  
Daily Insulin Dose

scholarly journals Basal Insulin Requirement Is  30% of the Total Daily Insulin Dose in Type 1 Diabetic Patients Who Use the Insulin Pump

Diabetes Care ◽  
2011 ◽  
Vol 34 (5) ◽  
pp. 1089-1090 ◽  
Author(s):  
A. Kuroda ◽  
H. Kaneto ◽  
T. Yasuda ◽  
M. Matsuhisa ◽  
K. Miyashita ◽  
...  
Keyword(s):  
Basal Insulin ◽  
Insulin Pump ◽  
Insulin Dose ◽  
Insulin Requirement ◽  
Diabetic Patients ◽  
Daily Insulin ◽  
Daily Insulin Dose ◽  
Type 1 Diabetic Patients

scholarly journals SAT-662 Effects of SGLT Inhibitors or GLP1 Analogues on Glucose Homeostasis and Body Weight in Patients with Type 1 Diabetes: A Network Meta-Analysis

2020 ◽  
Vol 4 (Supplement_1) ◽  
Author(s):  
Soo Lim ◽  
Kim Yoon Ji
Keyword(s):  
Type 1 Diabetes ◽  
Body Weight ◽  
Meta Analysis ◽  
Insulin Dose ◽  
Mixed Treatment Comparison ◽  
Treatment Comparison ◽  
Daily Insulin ◽  
Daily Insulin Dose ◽  
Comparison Results

Abstract Objective: Despite intensive insulin treatment in patients with type 1 diabetes (T1D), many of them do not reach the glycemic target goal. We performed a network meta-analysis to evaluate the efficacy and safety of additional therapy to insulin in patients with T1D. Methods: We searched CENTRAL, MEDLINE, EMBASE, and Science Citation Index Expanded from January 1970 until September 2019 to identify randomized controlled trials (RCTs) in T1D patients treated with insulin and metformin, sodium-glucose cotransporter (SGLT) inhibitors or glucagon-like peptide-1 receptor agonists (GLP-1 RAs). We performed direct and indirect network meta-analysis using Bayesian models and generated rankings of the different hypoglycemia agents by generating mixed treatment comparison. Results: With 23 RCTs (n = 5,151), we performed the network meta-analysis using eight groups; 1) insulin alone, 2) insulin and metformin, 3) insulin and canagliflozin, 4) insulin and dapagliflozin, 5) insulin and empagliflozin, 6) insulin and sotagliflozin, 7) insulin and liraglutide, and 8) insulin and exenatide. Compared with insulin alone, HbA1c was significantly lower in the group treated with insulin and sotagliflozin (mean difference: -0.43%; 95% credible intervals: -0.62 to -0.23). Total daily insulin dose was significantly lower in the insulin and sotagliflozin group by 6.3 U/day than in insulin alone group. Compared with insulin alone, body weight was significantly decreased in the group treated with canagliflozin by 4.5kg, sotagliflozin by 2.8kg, and exenatide by 5.1 kg, respectively. Severe hypoglycemic episodes did not differ between the groups. Conclusions: In patients with T1D, sotagliflozin add-on to insulin decreased HbA1c levels, daily insulin dose, and body weight without hypoglycemia compared to insulin monotherapy. Combined treatment of canagliflozin or exenatide with insulin was effective in weight loss compared with insulin alone in these patients.

Basal insulin and total daily insulin dose in children with type 1 diabetes using insulin pumps

2008 ◽  
Vol 9 (3pt1) ◽  
pp. 208-213 ◽  
Author(s):  
Ewa Pańkowska ◽  
Agnieszka Szypowska ◽  
Maria Lipka
Keyword(s):  
Type 1 Diabetes ◽  
Basal Insulin ◽  
Insulin Dose ◽  
Insulin Pumps ◽  
Daily Insulin ◽  
Daily Insulin Dose

scholarly journals Multicenter, Open-Label, Two-Arm, Pilot Trial for Safety Reduction of Basal Insulin Dose Combined with SGLT2 Inhibitor in Type 1 Diabetes Mellitus: Study Protocol for RISING-STAR.

2020 ◽  
Author(s):  
Masahide Hamaguchi ◽  
Yoshitaka Hashimoto ◽  
Toru Tanaka ◽  
Goji Hasegawa ◽  
Michiyo Ishii ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 1 Diabetes ◽  
Type 1 Diabetes Mellitus ◽  
Basal Insulin ◽  
Insulin Dose ◽  
Sglt2 Inhibitor ◽  
Daily Insulin ◽  
Daily Insulin Dose ◽  
Daily Dose

Abstract Background: SGLT2 inhibitor combined with insulin therapy is a novel therapy for patients with type 1 diabetes mellitus. Without the reduction of basal insulin, hypoglycemia could occur frequently in this therapy. But diabetic ketoacidosis is an undesirable adverse effect in case with basal insulin reduction. The aim of this study is to explore whether the reduction of the basal insulin dose combined with SGLT2 inhibitor in patients with type 1 diabetes mellitus can reduce the frequency of hypoglycemia and be used safely. We hypothesized that with an adequate basal insulin dose, the frequency of hypoglycemia is higher if the basal insulin dose is not reduced when combined with SGLT2 inhibitor.Methods and Analysis: The study has a two-arm design; 60 subjects with type 1 diabetes mellitus are being recruited from 7 hospitals. The basal insulin dose before the start of the SGLT2 inhibitor combination therapy is the reference. Study subjects are stratified into two groups based on the ratio of basal insulin daily dose (Basal) to total daily insulin dose (TDD). The subjects are instructed to reduce the basal insulin dose by 10% or 0% for Basal to TDD ratio of <0.4 and > 0.4, respectively.The primary outcome is the frequency of hypoglycemia per day during the intervention period (administration of SGLT2 inhibitor) as determined by self-monitoring of blood glucose (SMBG). The secondary outcome is the frequency of ketosis before and after the intervention. Discussion: 10% basal insulin reduction could reduce hypoglycemia as well as could not increase ketosis in case that the ratio of basal insulin daily dose to total daily insulin dose is 0.4 or higher, which improve the efficacy and safety of SGLT2 inhibitor treatment patients with type 1 diabetes mellitus.Ethics and Dissemination: The study was approved by Kyoto Prefectural University of Medicine, Clinical Research Review Board (CRB5180001). The results will be disseminated through presentations at appropriate conferences and meetings, and published in peer-reviewed journals.Trial registration: Registered with Japan Registry of Clinical Trials (jRCTs051190114) on 2 March, 2020. https://rctportal.niph.go.jp/detail/jr?trial_id=jRCTs051190114)

scholarly journals The association between overweight/obesity and double diabetes in adults with type 1 diabetes; a cross-sectional study

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Nathan WP Cantley ◽  
Kathryn Lonnen ◽  
Ioannis Kyrou ◽  
Abd A Tahrani ◽  
Hassan Kahal
Keyword(s):  
Type 1 Diabetes ◽  
Insulin Dose ◽  
Cross Sectional Study ◽  
Care Hospital ◽  
Sectional Study ◽  
Cross Sectional ◽  
Daily Insulin ◽  
Daily Insulin Dose ◽  
Double Diabetes

Abstract Background Double Diabetes (DD), type 1 diabetes (T1DM) + insulin resistance (IR), is associated with increased risk of micro/macro-vascular complications and mortality. Obesity can contribute to the development of DD. This study explored the prevalence of overweight/obesity and their association with DD in adults with T1DM. Methods Cross-sectional study of consecutive adults with T1DM attending diabetes clinics in a secondary care hospital (January-November 2019). Estimated glucose disposal rate (eGDR) was used as a marker of IR, and an eGDR < 8 was used to identify individuals with DD. Results One hundred seven adults with T1DM were included; female/male: 51/56; age [median (inter-quartile range): 30.0 (23–51) years]; BMI 25.4 (22.8–30.0) kg/m2. Overweight/obesity prevalence was 57/107 (53.3 %) [overweight: 30/107 (28 %); obesity: 27/107 (25.2 %)]. Compared to those with normal BMI, individuals with T1DM and overweight/obesity had longer diabetes duration; higher total daily insulin dose; and higher DD prevalence: 48/57 (84.2 %) vs. 14/50 (28 %) (p < 0.01); with similar HbA1c. BMI correlated with total daily insulin dose (rho = 0.55; p < 0.01). Individuals with DD were older, had longer duration of diabetes, higher HbA1c, and more adverse lipid profile and microalbuminuria compared to those without DD. Conclusions Overweight/obesity is very common in adults with T1DM, and is associated with double diabetes. BMI is positively associated with total insulin dose. Double diabetes is associated with adverse cardiovascular risk profile and is also common in lean individuals with T1DM. Further research is needed to examine the impact of overweight/obesity in people with T1DM and whether weight loss in this population can improve diabetes-related outcomes.

Sign in / Sign up

Export Citation Format

Share Document